Characterizing Outcomes and Unmet Needs Among Patients in the United States with Mild-to-Moderate Plaque Psoriasis Using Prescription Topicals

Shaloo Gupta; Steven Garbarini; Tara Nazareth; Ibrahim Khilfeh; Halley Costantino; David Kaplan

doi:10.1007/s13555-021-00620-x

Abstract

1 min read

Contrary to their treatment goals, patients with mild-to-moderate PSO using prescription topicals reported partial effectiveness, incomplete symptom resolution, impacted emotional and social well-being, and suboptimal global satisfaction, effectiveness, adherence, and convenience. Our findings highlight several unmet needs among topical-experienced, systemic-naïve patients with mild-to-moderate PSO using prescription topicals.

Related publications

Article2022

Real-world health outcomes in US adult patients with mild to moderate plaque psoriasis taking topical therapy

David Kaplan, James Hetherington, James Lucas, Ibrahim Khilfeh, Tara Nazareth

Article2023

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Clay Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Em Griffiths

Article2025

Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, Carolin Daamen, Christopher Em Griffiths

Article2023

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher Em Griffiths

Article2008

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

Jean‐Paul Ortonne, Christopher Em Griffiths, E. Daudén, Robert Strohal, Deborah Robertson, Ronald Pedersen, C. Molta, Bruce Freundlich